本文關(guān)鍵詞：女性型禿發(fā)患者的缺鐵狀況研究　出處：《復(fù)旦大學(xué)》2013年博士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 女性型禿發(fā) 鐵缺乏 鐵蛋白

【摘要】：背景 女性型禿發(fā)是一種非常常見的疾病,且對(duì)女性患者的生活質(zhì)量造成明顯影響。部分研究表明禿發(fā)患者常見鐵缺乏,包括斑禿、女性型禿發(fā)、休止期禿發(fā)等,也有部分研究質(zhì)疑該觀點(diǎn)。但是目前關(guān)于鐵缺乏的定義仍不十分明確,包括哪種指標(biāo)能準(zhǔn)確反映體內(nèi)鐵儲(chǔ)狀態(tài)仍不明確,部分研究認(rèn)為鐵蛋白相對(duì)更能反映體內(nèi)鐵儲(chǔ)狀態(tài)。即便以鐵蛋白作為體內(nèi)鐵儲(chǔ)狀態(tài)的指標(biāo),鐵蛋白要低至何種程度才說明體內(nèi)鐵缺乏仍無明確定義。 目的 有研究認(rèn)為女性型禿發(fā)與鐵缺乏有關(guān),也有研究質(zhì)疑該觀點(diǎn)。本研究的目的是研究鐵缺乏在女性型禿發(fā)患者中的發(fā)病情況及相關(guān)影響因素。 方法 收集復(fù)旦大學(xué)附屬華山醫(yī)院皮膚科脫發(fā)專病門診2011年7月至2013年03月間診斷為女性型禿發(fā)的429例女性病例組。收集通過社區(qū)隨機(jī)抽取并符合條件的142例正常女性人群為對(duì)照組。對(duì)病例組和對(duì)照組分別進(jìn)行血清鐵蛋白、總鐵結(jié)合力、未飽和轉(zhuǎn)鐵蛋白、血清鐵、轉(zhuǎn)鐵蛋白飽和度值的比較。并分別以鐵蛋白≤15μg/L、鐵蛋白≤40μg/L、鐵蛋白≤70μg/L作為鐵缺乏的界限對(duì)病例組和對(duì)照組進(jìn)行鐵缺乏發(fā)生率的比較。并且區(qū)分未絕經(jīng)人群與絕經(jīng)人群了解病例組和對(duì)照組鐵代謝各項(xiàng)參數(shù)及鐵缺乏發(fā)生率是否有統(tǒng)計(jì)學(xué)差異。因?yàn)橛醒芯空J(rèn)為鐵缺乏和肥胖、胰島素抵抗有關(guān),故本研究對(duì)病例組進(jìn)行身高、體重、腰圍、臀圍、空腹胰島素和血糖的檢測,從而比較病例組中鐵缺乏人群和鐵未缺乏人群的體重指數(shù)、腰臀比、胰島素抵抗指數(shù)是否有顯著性差異,以此排除肥胖、胰島素抵抗的干擾因素。 結(jié)果 一.一般資料 1.1樣本量： 病例組429例,其中未絕經(jīng)患者364例(84.8%),絕經(jīng)患者65例(15.2%)；對(duì)照組142例,未絕經(jīng)人數(shù)88例(62.0%),絕經(jīng)人數(shù)54例(38.0%)。1.2年齡： 病例組和對(duì)照組年齡分別為35.65歲(95%可信區(qū)間為18-60歲)和44.54歲(95%可信區(qū)間18-69歲)；未絕經(jīng)人群病例組和對(duì)照組年齡分別為31.83歲(95%可信區(qū)間17-49歲)和35.09歲(95%可信區(qū)間為15-50歲)；絕經(jīng)人群病例組和對(duì)照組年齡分別為57.02歲(95%可信區(qū)間為51-59歲)和59.94歲(95%可信區(qū)間為51-70歲)。不管是否區(qū)分未絕經(jīng)人群與絕經(jīng)人群,對(duì)照組年齡顯著高于病例組(P0.001,P=0.006,P=0.004)。 二.鐵代謝參數(shù) 2.1鐵蛋白： 病例組和對(duì)照組鐵蛋白分別為56.49μg/L(95%可信區(qū)間：5.62-216.04μg/L)和144.90μg/L(95%可信區(qū)間：8.73-596.31μg/L),未絕經(jīng)人群中病例組和對(duì)照組鐵蛋白分別為43.85μg/L(95%可信區(qū)間：5.53-140.14μg/L)和100.45(95%可信區(qū)間：5.93-363.21μg/L),絕經(jīng)人群中病例組和對(duì)照組鐵蛋白分別為127.32μg/L(95%可信區(qū)間：22.50-407.13gg/L)和217.34μg/L(95%可信區(qū)間：23.10-595.90μg/L),不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,對(duì)照組鐵蛋白顯著高于病例組(P0.001)。 當(dāng)鐵蛋白≤15μg/L作為鐵缺乏的界限時(shí),病例組和對(duì)照組分別有74例(17.2%)和16例(11.3%)鐵缺乏,未絕經(jīng)人群中病例組和對(duì)照組分別有73例(20.1%)和16例(18.2%)鐵缺乏,絕經(jīng)人群中病例組和對(duì)照組分別有1例(1.5%)和0例(0%)鐵缺乏。無論是否區(qū)分未絕經(jīng)人群與絕經(jīng)人群,病例組與對(duì)照組鐵缺乏的發(fā)生率無統(tǒng)計(jì)學(xué)差異(P=0.09,P=0.692,P=0.362)。 當(dāng)鐵蛋白≤40μg/L作為鐵缺乏的界限,病例組和對(duì)照組分別有219例(52.1%)和40例(28.2%)鐵缺乏,未絕經(jīng)人群中病例組和對(duì)照組分別有214例(58.8%)和36例(40.9%)鐵缺乏,絕經(jīng)人群中病例組和對(duì)照組分別有5例(7.7%)和4例(7.4%)鐵缺乏。若不區(qū)分絕經(jīng)人群與未絕經(jīng)人群,病例組鐵缺乏的發(fā)生率顯著高于對(duì)照組(P0.001)。在未絕經(jīng)人群中,病例組鐵缺乏的發(fā)生率顯著高于對(duì)照組(P=0.002)。但在絕經(jīng)人群中,病例組和對(duì)照組鐵缺乏發(fā)生率無統(tǒng)計(jì)學(xué)差異(P=1)。 當(dāng)鐵蛋白≤70gg/L作為鐵缺乏的界限,病例組和對(duì)照組分別有325例(75.8%)和55例(38.7%)鐵缺乏,未絕經(jīng)人群中病例組和對(duì)照組分別有308例(84.6%)和47例(53.4%)鐵缺乏,絕經(jīng)人群中病例組和對(duì)照組分別有20例(30.8%)和8例(14.8%)鐵缺乏。不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組鐵缺乏的發(fā)生率顯著高于對(duì)照組(P0.001,P0.001,P=0.041)。 2.2總鐵結(jié)合力： 病例組和對(duì)照組總鐵結(jié)合力分別為58.38μmol/L(95%可信區(qū)間：44.08-79.92μmol/L)和50.86μmol/L(95%可信區(qū)間：32.81-69.87μmol/L),未絕經(jīng)人群病例組和對(duì)照組總鐵結(jié)合力分別為58.84μmol/L(95%可信區(qū)間：44.12.92-81.36μmol/L)和52.78μmol/L(95%可信區(qū)間：35.03-69.84μmol/L),絕經(jīng)人群病例組和對(duì)照組總鐵結(jié)合力分別為55.78μmol/L(95%可信區(qū)間：42.33-67.27μmol/L)和47.71μmol/L(95%可信區(qū)間：31.62-70.91μmol/L),不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組總鐵結(jié)合力顯著高于對(duì)照組(P0.001)。 2.3未飽和轉(zhuǎn)鐵蛋白： 病例組和對(duì)照組未飽和轉(zhuǎn)鐵蛋白分別為41.82pmol/L(95%可信區(qū)間：21.32-72.12pmol/L)和34.90pmol/L(95%可信區(qū)間：12.70-58.55pmol/L),未絕經(jīng)人群中病例組和對(duì)照組未飽和轉(zhuǎn)鐵蛋白分別為42.67pmol/L(95%可信區(qū)間：21.61-72.84pmol,/L)和36.75pmol/L(95%可信區(qū)間：8.82-60.63pmol/L),絕經(jīng)人群中病例組和對(duì)照組未飽和轉(zhuǎn)鐵蛋白分別為37.05pmol/L(95%可信區(qū)間：19.73-61.24pmol/L)和31.88pmol/L(95%可信區(qū)間：12.72-46.61pmol/L),不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組未飽和轉(zhuǎn)鐵蛋白顯著高于對(duì)照組(P0.001,P=0.001,P=0.002)。 2.4血清鐵： 病例組和對(duì)照組血清鐵分別為16.51μmol/L(95%可信區(qū)間：5.62-29.76μmol/L)和15.96μmol/L(95%可信區(qū)間:4.82-30.19μmol/L),未絕經(jīng)人群中病例組和對(duì)照組血清鐵分別為16.12μmol/L(95%可信區(qū)間：5.51-29.74μmol,/L)和16.04μmol/L(95%可信區(qū)間：3.23-31.62μmol/L),絕經(jīng)人群中病例組和對(duì)照組血清鐵分別為16.73μmol/L(95%可信區(qū)間：6.12-36.83μmol/L)和15.83μmol/L(95%可信區(qū)間：6.61-28.47μmol/L),不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組和對(duì)照組血清鐵比較無統(tǒng)計(jì)學(xué)差異(P=0.326,P=0.796,P=0.154)。 2.5轉(zhuǎn)鐵蛋白飽和度： 病例組和對(duì)照組轉(zhuǎn)鐵蛋白飽和度分別為29.49%(95%可信區(qū)間：8.01%-57.32%)和30.59%(95%可信區(qū)間：5.14%-66.32%),未絕經(jīng)人群中病例組和對(duì)照組轉(zhuǎn)鐵蛋白飽和度分別為28.65%(95%可信區(qū)間：8.03%-57.17%)和29.81%(95%可信區(qū)間：5.12%-66.76%),絕經(jīng)人群中病例組和對(duì)照組轉(zhuǎn)鐵蛋白飽和度分別為34.14%(95%可信區(qū)間：9.15%-65.31%)和31.88%(95%可信區(qū)間：19.14%-42.30%),不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組和對(duì)照組轉(zhuǎn)鐵蛋白飽和度比較均無統(tǒng)計(jì)學(xué)差異(P=0.208, P=0.251, P=0.124)。 三.鐵代謝干擾因素 3.1體重指數(shù)： 以鐵蛋白≤40gg/L作為鐵缺乏的界限值,病例組中鐵缺乏人群和鐵未缺乏人群體重指數(shù)分別為20.99(95%可信區(qū)間：17.22-26.73)和21.37(95%可信區(qū)間：17.58-27.77)；未絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群體重指數(shù)分別為20.93(95%可信區(qū)間：17.22-26.35)和21.29(95%可信區(qū)間：17.58-28.23)；絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群體重指數(shù)分別為23.47(95%可信區(qū)間：20.43-29.69)和21.57(95%可信區(qū)間：17.4-29.21)。不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組中鐵缺乏人群和鐵未缺乏人群體重指數(shù)比較均無顯著性差異(P=0.270,P=0.332,P=0.241)。 3.2腰臀比： 以鐵蛋白≤40gg/L作為鐵缺乏的界限值,病例組中鐵缺乏人群和鐵未缺乏人群腰臀比分別為0.76(95%可信區(qū)間：0.67-0.89)和0.78(95%可信區(qū)間：0.69-0.93)；未絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群腰臀比分別為0.77(95%可信區(qū)間：0.67-0.88)和0.78(95%可信區(qū)間：0.69-0.90)；絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群腰臀比分別為0.78(95%可信區(qū)間：0.72-0.93)和0.79(95%可信區(qū)間：0.69-0.99)。不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組中鐵缺乏人群和鐵未缺乏人群腰臀比比較均無顯著性差異(P=0.082,P=0.201,P=0.341)。 3.3胰島素抵抗指數(shù)： 以鐵蛋白≤40μg/L作為鐵缺乏的界限值,病例組中鐵缺乏人群和鐵未缺乏人群胰島素抵抗指數(shù)分別為1.66(95%可信區(qū)間：0.55-4.33)和1.86(95%可信區(qū)間：0.62-5.25)；未絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群胰島素抵抗指數(shù)分別為1.66(95%可信區(qū)間：0.55-4.14)和1.85(95%可信區(qū)間：0.64-5.25)；絕經(jīng)人群中,病例組中鐵缺乏人群和鐵未缺乏人群胰島素抵抗指數(shù)分別為1.87(95%可信區(qū)間：0.66-5.35)和1.88(95%可信區(qū)間：0.59-6.22)。不管是否區(qū)分未絕經(jīng)人群和絕經(jīng)人群,病例組中鐵缺乏人群和鐵未缺乏人群胰島素抵抗指數(shù)比較均無顯著性差異(P=0.446, P=0.284, P=0.283)。 結(jié)論 本研究提示鐵缺乏與女性型禿發(fā)存在一定的相關(guān)性,如能通過補(bǔ)鐵進(jìn)一步證實(shí)鐵缺乏在女性型禿發(fā)發(fā)病中的作用,則為女性型禿發(fā)的治療提供新的策略,具體分子機(jī)制有待進(jìn)一步研究。我們建議鐵蛋白≤40μg/L作為鐵缺乏的界限值。本研究的特點(diǎn)在于進(jìn)行了多參數(shù)的評(píng)估,且結(jié)果基本一致,排除了肥胖、胰島素抵抗的干擾困素,結(jié)果可靠性高。
[Abstract]:background
Female pattern baldness is a very common disease, and caused significant impact on women's quality of life of patients. Some studies show that the lack of iron, including common alopecia patients with alopecia areata, female pattern baldness, telogen alopecia, there are some studies questioned the view. But at present a definition of iron deficiency is still not very clear, including what kind of index can accurately reflect the state of body iron stores are still not clear, part of the research that ferritin could reflect the relative iron storage state. Even in the iron in iron storage protein as the index, to the extent to which low ferritin only that iron deficiency is still no clear definition.
objective
Studies have suggested that female alopecia is related to iron deficiency. There are also studies that question this view. The purpose of this study is to investigate the incidence and related factors of iron deficiency in female patients with alopecia.
Method
From the Department of Dermatology of Huashan Hospital Affiliated to Fudan University alopecia clinic from July 2011 to 2013 03 months was diagnosed in 429 cases of female patients were female pattern baldness. Collected 142 cases of normal women were selected by the community and meet the conditions for the control group. The case group and control group respectively, serum ferritin, total iron binding capacity, unsaturated transferrin comparison of serum iron, transferrin saturation, value. And the ferritin is less than or equal to 15 mu g/L, ferritin is less than or equal to 40 mu g/L, ferritin is less than or equal to 70 g/L as the threshold of iron deficiency in the case group and control group were compared. The incidence of iron deficiency and does not distinguish between menopause and menopause patients and understand the control group of iron metabolism parameters and the incidence of iron deficiency is statistically significant. Because studies have shown that iron deficiency and obesity, insulin resistance, so the study of case group were higher, Body weight, waist circumference, hip circumference, fasting insulin and blood glucose were detected. The body mass index, waist hip ratio and insulin resistance index of iron deficiency group and iron deficient population in case group were compared, so as to exclude the interference factors of obesity and insulin resistance.
Result
I. General Information
1.1 sample size:
There were 429 cases in the case group, including 364 cases of non menopausal women (84.8%), 65 cases (15.2%) of menopausal women, 142 cases of control group, 88 cases (62%) of menopause, 54 cases (38%) of menopause,.1.2 age:
The case group and the control group were 35.65 years of age (95% confidence interval 18-60 years) and 44.54 (95% confidence interval 18-69 years); no cases of menopause group and control group were 31.83 years of age (95% confidence interval 17-49 years) and 35.09 (95% confidence interval for 15-50 years of menopause cases); group and control group were 57.02 years of age (95% confidence interval 51-59 years) and 59.94 (95% Ci, 51-70 years). No matter whether to distinguish between premenopausal and postmenopausal population groups, the control group was significantly higher than that of age group (P0.001, P=0.006, P=0.004).
Two. Iron metabolic parameters
2.1 ferritin:
The case group and the control group of ferritin were 56.49 g/L (95% CI: 5.62-216.04 g/L) and 144.90 g/L (95% CI: 8.73-596.31 g/L), no cases of menopause in control group and ferritin were 43.85 g/L (95% confidence interval: 5.53-140.14 g/L (95% and 100.45) confidence interval: 5.93-363.21 g/L), menopause in case group and control group ferritin were 127.32 g/L (95% CI: 22.50-407.13gg/L) and 217.34 g/L (95% CI: 23.10-595.90 g/L), regardless of whether the distinction between premenopausal and the vast population by population group was significantly higher than that of control group cases of ferritin (P0.001).
When ferritin is less than or equal to 15 mu g/L as the threshold of iron deficiency, the case group and the control group were 74 cases (17.2%) and 16 (11.3%) cases of iron deficiency, not menopause in case group and control group were 73 cases (20.1%) and 16 (18.2%) cases of iron deficiency, in cases of menopause and the control group were 1 cases (1.5%) and 0 cases (0%). No matter whether iron deficiency does not distinguish between menopause and menopause group, the case group and the control group the incidence of iron deficiency had no significant difference (P=0.09, P=0.692, P=0.362).
When ferritin is less than or equal to 40 mu g/L as the threshold of iron deficiency, the case group and the control group were 219 cases (52.1%) and 40 (28.2%) cases of iron deficiency, not menopause in case group and control group were 214 cases (58.8%) and 36 (40.9%) cases of iron deficiency, cases of menopause in and the control group were 5 cases (7.7%) and 4 cases (7.4%) of iron deficiency. If do not distinguish between menopause and premenopausal population, incidence of iron deficiency in case group was significantly higher than the control group (P0.001). In premenopausal group, the incidence of iron deficiency in case group was significantly higher than the control group (P=0.002). But in the case of menopause, iron deficiency group and the control group there was no significant difference (P=1).
When ferritin is less than or equal to 70gg/L as the limits of iron deficiency, the case group and the control group were 325 cases (75.8%) and 55 (38.7%) cases of iron deficiency, not menopause in case group and control group were 308 cases (84.6%) and 47 (53.4%) cases of iron deficiency, menopause in cases and controls group there were 20 cases (30.8%) and 8 cases (14.8%). No matter whether iron deficiency does not distinguish between menopause and menopause population, incidence of iron deficiency in case group was significantly higher than the control group (P0.001, P0.001, P=0.041).
2.2 total iron junctions:
The case group and the control group in the total iron binding capacity were 58.38 mol/L (95% CI: 44.08-79.92 mol/L) and 50.86 mol/L (95% CI: 32.81-69.87 mol/L), not menopause patients and the control group total iron binding capacity were 58.84 mol/L (95% confidence interval: 44.12.92-81.36 and mol/L) 52.78 mol/L (95% CI: 35.03-69.84 mol/L), menopause patients group and control group total iron binding capacity were 55.78 mol/L (95% CI: 42.33-67.27 mol/L) and 47.71 mol/L (95% CI: 31.62-70.91 mol/L), regardless of whether the distinction between premenopausal and postmenopausal population groups, the case group the total iron binding capacity was significantly higher than the control group (P0.001).
2.3 unsaturated transferrin:
The case group and the control group without transferrin saturation were 41.82pmol/L (95% CI: 21.32-72.12pmol/L) and 34.90pmol/L (95% CI: 12.70-58.55pmol/L), among premenopausal patients and the control group without transferrin saturation were 42.67pmol/L (95% CI: 21.61-72.84pmol, /L) and 36.75pmol/L (95% CI: 8.82-60.63pmol/L), menopause in the case group and the control group without transferrin saturation were 37.05pmol/L (95% CI: 19.73-61.24pmol/L) and 31.88pmol/L (95% CI: 12.72-46.61pmol/L), regardless of whether the distinction between premenopausal and postmenopausal population groups, the case group of unsaturated transferrin was significantly higher than the control group (P0.001, P=0.001, P=0.002).
2.4 serum iron:
The case group and the control group of serum iron were 16.51 mol/L (95% CI: 5.62-29.76 mol/L) and 15.96 mol/L (95% CI: 4.82-30.19 mol/L), no cases of menopause in control group and serum iron were 16.12 mol/L (95% confidence interval: 5.51-29.74 mol, /L) and 16.04 mol/L (95% CI: 3.23-31.62 mol/L), menopause in case group and control group respectively, serum iron was 16.73 mol/L (95% CI: 6.12-36.83 mol/L) and 15.83 mol/L (95% CI: 6.61-28.47 mol/L), regardless of whether the distinction between premenopausal and postmenopausal population groups, cases and controls there was no significant difference in serum iron (P=0.326, P=0.796, P=0.154).
2.5 transferrin saturation:
The case group and the control group were 29.49% transferrin saturation (95% CI: 8.01%-57.32%) and 30.59% (95% CI: 5.14%-66.32%), no cases of menopause in control group and transferrin saturation were 28.65% (95% CI: 8.03%-57.17%) and 29.81% (95% CI: 5.12%-66.76%), menopause in case group and the control group were 34.14% transferrin saturation (95% CI: 9.15%-65.31%) and 31.88% (95% CI: 19.14%-42.30%), regardless of whether the distinction between premenopausal and postmenopausal population groups, the case group and the control group transferrin saturation were no statistically significant difference (P=0.208, P=0.251, P=0.124).
Three. Interference factors of iron metabolism
3.1 body mass index (BMI):
In order to ferritin than 40gg/L as the limits of iron deficiency, iron deficiency and iron were not the lack of crowd crowd weight index were 20.99 (95% CI: 17.22-26.73) and 21.37 (95% CI: 17.58-27.77); premenopausal population, cases of iron deficiency and iron deficient population population without weight index were 20.93 (95% CI: 17.22-26.35) and 21.29 (95% CI: 17.58-28.23); menopause in cases of iron deficiency and iron deficient population population without weight index were 23.47 (95% CI: 20.43-29.69) and 21.57 (95% CI: 17.4-29.21). No matter whether to distinguish between premenopausal and postmenopausal population groups, cases group of iron deficiency and iron deficient population population without BMI had no significant difference (P=0.270, P=0.332, P=0.241).
3.2 waist to hip ratio:
In order to ferritin than 40gg/L as the limits of iron deficiency, iron deficiency and iron were not lack of people crowd the waist to hip ratio was 0.76 (95% CI: 0.67-0.89) and 0.78 (95% CI: 0.69-0.93); premenopausal population, cases of iron deficiency and iron deficient population population without waist to hip ratio respectively. 0.77 (95% CI: 0.67-0.88) and 0.78 (95% CI: 0.69-0.90); menopause in cases of iron deficiency and iron deficient population population without waist to hip ratio was 0.78 (95% CI: 0.72-0.93) and 0.79 (95% confidence interval: 0.69-0.99). No matter whether to distinguish between premenopausal and population menopause, cases of iron deficiency and iron deficient population population not WHR had no significant difference (P=0.082, P=0.201, P=0.341).
3.3 insulin resistance index:
In the Fe protein is less than or equal to 40 mu g/L as the boundary value of iron deficiency, iron deficiency and iron were not crowd people lacking insulin resistance index were 1.66 (95% CI: 0.55-4.33) and 1.86 (95% CI: 0.62-5.25); premenopausal population, cases of iron deficiency and iron deficiency group without insulin the resistance index was 1.66 (95% CI: 0.55-4.14) and 1.85 (95% CI: 0.64-5.25); menopause in cases of iron deficiency and iron deficient population population without insulin resistance index were 1.87 (95% CI: 0.66-5.35) and 1.88 (95% CI: 0.59-6.22). No matter whether to distinguish between premenopausal the crowd and the menopause, cases of iron deficiency and iron deficient population population without insulin resistance index had no significant difference (P=0.446, P=0.284, P=0.283).
conclusion
This study suggests that iron deficiency in women with alopecia type has certain relevance, such as through iron supplementation in the pathogenesis of female pattern baldness further confirmed the role of iron deficiency, then provide a new strategy for the treatment of female pattern baldness, needs further research. We suggest that the molecular mechanism of ferritin is less than or equal to 40 g/L as the threshold of iron deficiency value. The characteristics of this study is to evaluate the parameters, and the results are basically the same, excluding obesity, insulin resistance and interference factors, the reliability is high.

【學(xué)位授予單位】：復(fù)旦大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2013
【分類號(hào)】：R758.71

【共引文獻(xiàn)】

相關(guān)博士學(xué)位論文 前1條

1 胡瑞銘;口服非那雄胺1mg/d、外用5%米諾地爾溶液及聯(lián)合治療男性雄激素性禿發(fā)的療效評(píng)估及相關(guān)血清學(xué)變化[D];復(fù)旦大學(xué);2013年

相關(guān)碩士學(xué)位論文 前4條

1 董瑛;歐美人群雄激素性脫發(fā)易感位點(diǎn)與漢族人群相關(guān)性研究[D];安徽醫(yī)科大學(xué);2013年

2 宋志華;男性與女性濕熱型雄激素性脫發(fā)能譜分析的比較研究[D];南京中醫(yī)藥大學(xué);2013年

3 廖金鳳;齊墩果酸對(duì)小鼠雄激素性脫發(fā)治療作用的研究[D];瀘州醫(yī)學(xué)院;2013年

4 尹益均;祛濕生發(fā)湯治療濕熱證女性型脫發(fā)臨床療效觀察[D];南京中醫(yī)藥大學(xué);2014年

，

本文編號(hào)：1366744